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Abstract
Background: Individuals with unrecognized myocardial infarctions (UMIs) detected with cardiovascular magnetic
resonance (CMR) constitute a recently defined group whose prognosis has not been fully evaluated. However,
increasing evidence indicate that these individuals may be at considerable cardiovascular risk. The aim of the
present study was to investigate the prognostic impact of CMR detected UMIs for major adverse cardiac events
(MACE) in community living elderly individuals.
Methods: Late gadolinium enhancement CMR was performed in 248 randomly chosen 70-year-olds. Individuals
with myocardial infarction (MI) scars, with or without a hospital diagnosis of MI were classified as recognized MI
(RMI) or UMI, respectively. Medical records and death certificates were scrutinized. MACE was defined as cardiac
death, non-fatal MI, a new diagnosis of angina pectoris, or symptom-driven coronary artery revascularization.
Results: During follow-up (mean 11 years) MACE occurred in 10 % (n = 18/182) of the individuals without MI scars,
in 20 % (n = 11/55) of the individuals with UMI, and in 45 % (n = 5/11) of the individuals with RMI, with a significant
difference between the UMI group and the group without MI scars (p = 0.045), and between the RMI group and
the group without MI scars (p = 0.0004). Cardiac death and/or non-fatal MI occurred in 15, 5, and 3 of the individuals in
the NoMI, UMI, and RMI group respectively. Hazards ratios for MACE adjusted for risk factors and sex were 2.55 (95 % CI
1.20-5.42; p = 0.015) for UMI and 3.28 (95 % CI1.16-9.22; p = 0.025) for RMI.
Conclusions: The presence of a CMR detected UMI entailed a more than double risk for MACE in community living
70-year-old individuals.
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Background
During a century the prevalence of unrecognized myo-
cardial infarctions (UMIs) has been estimated with elec-
trocardiography (ECG), using a persistent Q-wave as
sign of MI [1]. However, late gadolinium enhancement
cardiovascular magnetic resonance (LGE-CMR) detects
more UMIs than ECG [2], by depicting non-viable myo-
cardium [3]. Thus, ECG-detected and CMR detected
UMIs are not the same UMIs [2, 4, 5]. The prognosis of
an ECG-detected UMI is similar to that of a recognized
myocardial infarction (RMI) [6–8], whereas individuals
with CMR detected UMIs constitute a recently defined
group whose prognosis has not been as thoroughly in-
vestigated. However, increasing evidence indicate that
these individuals may be at considerable cardiovascular
risk [5, 9–14]..
A number of studies have been conducted in selected
risk populations establishing CMR detected UMIs as an
important risk factor for major adverse cardiac events
(MACE). This has been demonstrated in patients with
confirmed [9, 10] or suspected [9–11] coronary artery
disease, in patients with peripheral arterial occlusive
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disease [13], and in diabetic [12] and prediabetic [14]
patients.
Only one epidemiology study on the prognostic impact
of CMR detected UMIs has been published. It was per-
formed in a mixed cohort with randomly chosen partici-
pants and diabetes patients and it reveals an increased
all-cause mortality risk in elderly individuals with UMI
compared to those without MI [5]. To the best of our
knowledge, this is the first study to investigate the rela-
tionship between CMR detected UMIs and cardiac death
or other severe cardiac events in long-term follow-up of
an entirely population based cohort.
The aim of the present study was to investigate the
prognostic impact of CMR detected UMIs on cardiac
events in community living elderly individuals.
Methods
Study population
CMR was performed on an unselected subsample from
the Prospective Investigation of the Vasculature in Upp-
sala Seniors (PIVUS) study [15]. Eligible for the PIVUS
study were all individuals aged 70 years and resident in
the municipality of Uppsala, Sweden. The individuals
were chosen in a randomized manner from the register
of municipality inhabitants, and 2025 individuals were
invited to participate within weeks from their 70th birth-
day; 1016 agreed and gave written informed consent.
From the original cohort, 283 individuals were con-
secutively invited to undergo CMR, which was finally
performed on 259 individuals [2]. Their mean age was
71 years and 6 months (range 70 years, 5 months to
71 years, 10 months) when CMR was performed during
the years 2003–2005. The number of invited individuals
was preset, determined by financial limitations and the
availability of CMR scan time. Eleven examinations were
excluded because of poor image quality, leaving assess-
able data from 248 individuals (123 women, 125
men).184 of these individuals were reexamined five years
later (17 had died, 47 declined to participate).
The basic characteristics and major cardiovascular risk
factors of these individuals have been described else-
where [2] and did not differ significantly from those in
the entire PIVUS population [15], except that there were
fewer current smokers among the individuals of the
present study. The cardiac morbidity of the PIVUS study
participants did not differ significantly from that of the
background population [15].
Participant data and definitions
Medical records from all divisions of Uppsala University
Hospital and from all general practitioners in the county
were scrutinized by a doctor in September 2015 and data
on cardiac and atherosclerotic symptoms, morbidity and
mortality that occurred after the CMR examination were
collected. In cases when the individual was registered to
be deceased in the medical records, death certificates
were obtained and reviewed.
MACE was defined as cardiac death (i.e. cardiac arrest
being registered as the primary cause of death in the death
certificate), non-fatal MI (i.e. a hospital diagnosis of MI set
using the criteria defined by the Joint European Society of
Cardiology/American College of Cardiology Committee
[16]), a new diagnosis of angina pectoris, or symptom-
driven coronary artery revascularization. Only diagnoses
and events acquired or occurring after CMR were consid-
ered. In individuals with several MACEs, the time between
CMR and the first MACE was documented. The term
other cardiac morbidity includes diagnoses of arrhythmias,
congestive heart failure, or valvular disorders. The term
other atherosclerotic disease includes diagnoses of carotid
stenosis, renal artery stenosis, or peripheral arterial
disease.
Image acquisition and analysis
MR image acquisition and analysis has been described
elsewhere [2]. Briefly, a 1.5 Tesla MR system was used
(Gyroscan Intera, Philips Medical Systems, Best, the
Netherlands) to acquire late gadolinium enhancement
images after injection of 40 ml Gd-DTPA-BMA
(OmniscanTM, GE Healthcare, Oslo, Norway). At
70 years of age 40 ml gadolinium-diethylenetriamine
pentaacetic acid-bismethylamide (OmniscanTM, GE
Healthcare, Oslo, Norway) was administered in all indi-
viduals since a whole body MR angiography was per-
formed prior to acquiring the late gadolinium
enhancement images. At 75 years of age the contrast
dose was adjusted to body weight (0.2 mmol/kg).
Late gadolinium enhancement (LGE) images were ac-
quired using a 3D inversion recovery gradient echo se-
quence covering the entire heart in short and long axis
views. The acquired slice thickness was 10 mm with a
resolution of 1.56 x 2.81 mm and the inversion time was
individually adjusted. Cine images were acquired during
breath holding using asteady state free precession se-
quence as previously described [2, 17].
LGE images were assessed by two radiologists inde-
pendently and in a consensus reading, using subendocar-
dial involvement as a criterion for identifying MI scars
[18, 19]. The observers were blinded to each other’s as-
sessments and to information on any previous disease as
described elsewhere [2, 20]. The radiologists who ana-
lyzed the images acquired when the individuals were
75 years old were blinded to the analysis results from
images acquired when the individuals were 70 years old.
To avoid over reporting the prevalence of MI scars, an
additional consensus reading was performed in which
images displaying MI scars at either 70 or 75 years of
age were compared side by side with the images from
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the individual’s other MR examination and viability was
assessed also taking information from the cine images
into consideration.
The individuals were grouped based on the LGE-CMR
findings on images acquired when the individuals were
70 years old and the data from medical records: 182 had
no MI scar, 55 had a UMI (i.e. an MI scar [18, 19] but
no MI diagnosis), and 11 had an RMI (i.e. an MI scar in
combination with an MI diagnosis in medical records).
Statistical analysis
StatView version 5.0.1 (SAS Institute, Cary, North Carolina)
was used for statistical analyses. The Chi2-test was used for
estimating differences between groups. Cox’s Proportional
Hazards Model and the Kaplan-Meier method were used
to estimate event-free survival in the three groups. Im-
provement in discrimination by adding information on
UMI to the Framingham risk score was calculated with C-
statistics. The significance level was set at 0.05 in the pri-
mary analysis, i.e. the comparison between the UMI and
the NoMI groups. The comparison between the RMI and
the NoMI groups was regarded as a secondary analysis.
Results
The mean follow-up time was 11 years (range 9 years
and 10 months – 12 years and 7 months). No individuals
were lost to follow-up. Forty-eight of the 248 individuals
were deceased, 6 from cardiac arrest and 42 from non-
cardiac reasons (i.e. 17 from cancer, 4 from stroke, 6
from dementia or other degenerative disease, 5 from
trauma, and10 from infectious disease and/or organ
failure).
During follow-up, MACE occurred in 10 % (n = 18/182)
of the individuals without MI scars, in 20 % (n = 11/55) of
the individuals with UMI, and in 45 % (n = 5/11) of the in-
dividuals with RMI, with significant differences between
the UMI group and the group without MI scars
(p = 0.045) and between the RMI group and the group
without MI scars (p = 0.0004). (Fig. 1) In sex-specific ana-
lyses this difference was only significant between the
RMI group and the group without MI scars in men
(p = 0.0013). The distribution of MACE between the
groups and sexes is displayed in Table 1. Cardiac
death and/or non-fatal MI occurred in 15, 5, and 3
of the individuals in the NoMI, UMI, and RMI
group respectively.
The unadjusted hazards ratio (HR) for MACE for indi-
viduals with UMI was 2.62; 95 % confidence interval
(CI) 1.24-5.55; p = 0.012. The unadjusted HR for individ-
uals with RMI was 6.14; 95 % CI 2.27-16.6; p = 0.0003. A
Kaplan-Meier estimation of event-free survival is dis-
played in Fig. 2.
When adjusting for risk factors using the Framing-
ham Risk Score (FRS) [21] and for sex, UMI
remained associated with MACE (HR 2.55; 95 % CI
1.20-5.42; p = 0.015) whereas the association between
RMI and MACE was weakened (HR 3.28; 95 %
CI1.16-9.22; p = 0.025). HRs for FRS, and male sex
were; 1.18; 95 % CI 1.05-1.32; p = 0.007; and 2.43;
95 % CI 1.13-5.22; p = 0.023 respectively.
C-statistics for Framingham risk score was 0.68; CI
0.58-0.77. Adding information on UMIs increased C-
statistics to 0.75; CI 0.66-0.84 significantly (p = 0.0359).
Adding information on UMIs to the Framingham risk
score increased both IDI (0.068 (SE 0.022), p = 0.0020)
and category-free NRI (0.67(SE 0.20), p = 0.0007)
significantly.
The distribution of the events comprising MACE in
the three groups is displayed in Table 2.
Manifestations of other atherosclerotic disease (i.e. a
diagnosis of carotid or renal artery stenosis or peripheral
arterial disease) after the CMR examination were more
frequently diagnosed in individuals with UMI (16 %, i.e.
n = 9/55) than in individuals without MI scars (5 %, i.e.
n = 10/182) (p = 0.009). (Table 3) After the CMR examin-
ation, individuals with RMI acquired other cardiac diag-
noses (arrhythmias, congestive heart failure, or valvular
disorders) more frequently than those without MI scars
(p = 0.003). (Table 3)
There were no differences in the frequency of hyperten-
sion, diabetes, ischemic stroke, or chest pain symptoms
occurring after the CMR examination between the NoMI,

















Fig. 1 Distribution of MACE. The distribution of major adverse cardiac
events (MACE) (dark grey) in individuals without MI scars (NoMI) on CMR
in individuals with CMR detected unrecognized myocardial infarctions
(UMI), and in individuals with recognized myocardial infarction (RMI).
p-values of the differences are displayed in the figure
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used equally in the three groups. There were no differ-
ences in medication between the individuals with UMI
and those without MI scars.
Discussion
In the present cohort the presence of a UMI entailed a
more than double risk for MACE, also when adjusted
for cardiovascular risk factors and sex. This observation
confirms the results of other studies in selected [9–11,
13] and unselected populations [5]. Those studies were
performed mainly in populations with important risk
factors such as manifest atherosclerotic disease or dia-
betes, whereas the present study population was repre-
sentative of the general population. Thus, the results of
the present study imply that the prognostic impact of a
UMI might be important regardless of other risk factors.
MACE was more prevalent in men (n = 25) than in
women (n = 9) consistent with the known differences in
clinically recognized cardiac morbidity and mortality
[22]. However, MIs are more likely to be unrecognized
in women than in men [22], partly because women more
often present with atypical symptoms. [23–25] Conse-
quently, there is a possibility that other major cardiac
events may also be unrecognized in women. However,
the groups are too small to allow any such conclusion
from the present observations.
The weakened association between RMI and MACE
that was seen when adjusting for risk factors and sex
may be explained by the fact that 82 % (n = 9/11) of the
individuals with RMI were men. The observed increased
prevalence of cardiac death and angina in participants
with RMI was expected, as RMI is a well known risk fac-
tor for cardiac events [26, 27]. Since other cardiac mor-
bidity is associated with MI, it is not surprising that this
too would be frequent in the RMI group.
Other studies have demonstrated that LGE-CMR im-
proves risk stratification in patients [12] as well as in
population based samples [5]. The results of the present
study confirm this and may, thus, contribute in estab-
lishing CMR detected UMIs as a risk factor for MACE.
The risk for MACE may also be influenced by the size
of the MI scar, since. UMIs have been observed to be
generally smaller than RMIs [2, 13]. Thus, the presence
of a smaller MI scar (i.e. a UMI) entails an increased risk
for MACE compared to no MI scar, whereas the
presence of a larger MI scar (i.e. an RMI) entails an
even larger risk. These observations support the no-
tion that a CMR detected UMI appears to represent
an intermediate phenotype in the evolution of coron-
ary heart disease [5].
In the ICELAND MI study participants with UMI
were less likely to be treated with cardiovascular medica-
tions, such as statins than those with RMI [5]. No such
difference could be detected in the present study, which
may be due to low power since there were rather few
participants with RMI. In the ICELAND MI study 36 %
of the cohort had diabetes and participants with UMI
were more frequently treated with cardiovascular
Table 1 Distribution of major adverse cardiac events (MACE) between the sexes in individuals with or without myocardial scars on
cardiac magnetic resonance imaging
No MI (n = 182) UMI (n = 55) RMI (n = 11)
Men (n = 84) Women (n = 98) Men (n = 32) Women (n = 23) Men (n = 9) Women (n = 2)
MACE, number (%) 11 (13) 7 (7) 9 (28) 2 (9) 5 (6) 0



























Fig. 2 Event-free survival. Kaplan-Meier estimation of event-free survival in individuals without MI scars (NoMI) on cardiac magnetic resonance imaging,
in individuals with CMR detected unrecognized myocardial infarctions (UMI), and in individuals with recognized myocardial infarction (RMI)
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medications than participants without MI scars [5]. In
the present study cohort only 12 % had diabetes [2] and
there were no differences in medication between the in-
dividuals with UMI and those without MI scars. Thus,
the present cohort was slightly healthier (and/or not as
well treated). Despite these differences HR for MACE in
individuals with UMI was 2.55 in the present cohort and
1.45 in the ICELAND MI study [5], implying that UMI
may be an important risk factor also in otherwise
healthy individuals. Consequently, individuals with a
CMR detected UMI might benefit from cardioprotective
medication regardless of other cardiovascular risk fac-
tors. These individuals might need surveillance and pre-
ventive measures.
At baseline the prevalence of atherosclerotic disease
was increased in participants with RMI, but not in par-
ticipants with UMI compared to those without MI scars
in the present sample [28]. However, during the follow-
up period atherosclerotic diseases were more frequently
diagnosed in participants with UMI, but not in partici-
pants with RMI compared to those without MI scars.
(Table 3) The observation that individuals with RMI fre-
quently had other atherosclerotic diseases already at
baseline was expected. Furthermore, individuals with
these diagnoses are most likely under surveillance and
treatment which might explain why new atherosclerotic
manifestations were not frequently detected during
follow-up.
The observation that participants with UMI had an in-
creased prevalence of atherosclerotic disease at follow-
up but not at baseline suggests a more slowly progres-
sing disease in these individuals, compared to in those
with RMI. The fact that MACE was twice as prevalent
in individuals with UMI and more than four times as
prevalent in individuals with RMI compared to those
without MI scars in the present cohort (Fig. 1) may re-
flect an evolvement from subclinical to manifest
atherosclerosis.
The present study was limited by the fact that only
elderly Caucasians were studied and consequently the
observations may not be applicable to other ethnic or
age groups. The participants were consecutively in-
vited from a randomized cohort of community-living
individuals for the first CMR, and those who partici-
pated were invited for a second CMR five years later.
Creating a subsample of a subsample, which is un-
avoidable in a follow up study, might introduce a se-
lection bias. However, the cardiac morbidity of the
PIVUS study participants did not differ significantly
from that of the background population [15], and
basic characteristics and major cardiovascular risk fac-
tors did not differ between the present cohort and the
entire PIVUS population [15], except that there were
fewer current smokers among the individuals of the
present study. Thus, the present cohort might be
slightly healthier than the background population but
it is unlikely that this has affected the results in any
important way. Another limitation was that the indi-
viduals with RMI were rather few (n = 11). However,
the main purpose of this study was to investigate the
prognostic impact of UMI.
Conclusions
The presence of a CMR detected UMI entailed a more
than double risk for MACE in community living 70-
year-old individuals, also when adjusting for cardiovas-
cular risk factors and sex.
Table 2 Distribution of events regarded as major adverse cardiac events (MACE) in individuals with or without myocardial scars by
CMR. (One individual could have several events)
No MI (n = 182) No MI vs UMI UMI (n = 55) UMI vs RMI RMI (n = 11) RMI vs No MI
Cardiac Death 2 (1 %) ns 1 (2 %) p = 0.001 3 (27 %) p < 0.001
Non-fatal MI 15 (8 %) ns 4 (7 %) ns 3 (27 %) ns
Revascularization 13 (7 %) ns 6 (11 %) ns 2 (18 %) ns
Aquired Angina 10 (5 %) ns 6 (11 %) ns 3 (27 %) p = 0.005
No MI no MI scar, RMI recognized myocardial infarction, i.e., MI scar in combination with MI diagnosis in medical records, UMI unrecognized myocardial infarction
Table 3 Frequency of cardiovascular symptoms and diagnoses (not regarded as major adverse cardiac events) acquired after
70 years of age in individuals with or without myocardial scars by CMR
No MI (n = 182) No MI vs UMI UMI (n = 55) UMI vs RMI RMI (n = 11) RMI vs No MI
Ischemic stroke 4 (2 %) ns 3 (5 %) ns 0 ns
Chest pain symptoms 40 (22 %) ns 15 (27 %) ns 5 (45 %) ns
Other atherosclerosis 10 (5 %) p = 0.009 9 (16 %) ns 1 (5 %) ns
Other cardiac morbidity 32 (18 %) ns 15 (27 %) ns 6 (54 %) p = 0.003
No MI no MI scar, RMI recognized myocardial infarction, i.e., MI scar in combination with MI diagnosis in medical records, UMI unrecognized myocardial infarction
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